https://www.selleckchem.com/pr....oducts/lonidamine.ht
To explore the 10-year tolerability profile of GC use in patients with early RA. Analysis of 10-year outcome from the early arthritis ESPOIR cohort. Patients were stratified in two groups, without or with GC treatment at least once during their follow-up. The primary outcome was a composite of deaths, cardiovascular diseases (CVD), severe infections and fractures. The weighted Cox time-dependent analysis model was used with inverse probability of treatment weighting (IPTW) propensity score method. Among the 608 patients (480 women, m